Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpiTALL

Financiado

Cerrado

Dynamic interplay between DNA methylation histone modifications and super enhan...

Dynamic interplay between DNA methylation histone modifications and super enhancer activity in normal T cells and during malignant T cell transformation Dynamic interplay between histone modifications and DNA methylation defines the chromatin structure of the humane genome and serves as a conceptual framework to understand transcriptional regulation in normal development and human... ver más

30/06/2020

UGent

959K€

Presupuesto del proyecto: 959K€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-06-30

ERC-StG-2014: ERC Starting Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UGent

958.75K€ | Lider

INVESTIGACION Y DESARROLLO C...

250.46K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ONCOmetENHANCERS Elucidating the Role of Enhancer Methylation Variation in Ca... 2M€ Cerrado

DNAMETHYLOOPMCL Of DNA methylation and looping of distant regulatory element... 166K€ Cerrado

PID2020-112783GB-C22 REGULACION DE LA EXPRESION DE LAS VARIANTES SOMATICAS DE LA... 127K€ Cerrado

PID2019-111243RA-I00 DESCIFRANDO EL IMPACTO DE TET2 SOBRE LA ESTRUCTURA DE LA CRO... 145K€ Cerrado

EPICAL Systematic Identification and Validation of Epigenetic Cance... 100K€ Cerrado

SAF2012-31138 METILACION DIFERENCIAL DEL ADN EN REGIONES NO PROMOTORAS: RE... 70K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2015-06-11
Fecha Fin: 2020-06-30

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 959K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Dynamic interplay between histone modifications and DNA methylation defines the chromatin structure of the humane genome and serves as a conceptual framework to understand transcriptional regulation in normal development and human disease. The ultimate goal of this research proposal is to study the chromatin architecture during normal and malignant T cell differentiation in order to define how DNA methylation drives oncogenic gene expression as a novel concept in cancer research. T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of pediatric and 25% of adult ALL cases and was originally identified as a highly aggressive tumor entity. T-ALL therapy has been intensified leading to gradual improvements in survival. However, 20% of pediatric and 50% of adult T-ALL cases still relapse and ultimately die because of refractory disease. Research efforts have unravelled the complex genetic basis of T-ALL but failed to identify new promising targets for precision therapy. Recent studies have identified a subset of T-ALLs whose transcriptional programs resemble those of early T-cell progenitors (ETPs), myeloid precursors and hematopoietic stem cells. Importantly, these so-called ETP-ALLs are characterized by early treatment failure and an extremely poor prognosis. The unique ETP-ALL gene expression signature suggests that the epigenomic landscape in ETP-ALL is markedly different as compared to other genetic subtypes of human T-ALL. My project aims to identify genome-wide patterns of DNA methylation and histone modifications in genetic subtypes of human T-ALL as a basis for elucidating how DNA methylation drives the expression of critical oncogenes in the context of poor prognostic ETP-ALL. Given that these ETP-ALL patients completely fail current chemotherapy treatment, tackling this completely novel aspect of ETP-ALL genetics will yield new targets for therapeutic intervention in this aggressive haematological malignancy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores